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Abstract: Treatment of glioblastoma (GBM) consists of microsurgical resection followed by
concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding
progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of
a specialized neuro-oncology care center (NOC) has enabled the implementation of a large technical
portfolio including functional imaging, awake craniotomy, PET scanning, fluorescence-guided
resection, and integrated postsurgical therapy. This study analyzed whether the technically improved
neurosurgical treatment structure yields a higher rate of complete resection, thus ultimately improving
patient outcome. Patients and methods: The study included 149 patients treated surgically for newly
diagnosed GBM. The neurological performance score (NPS) and the Karnofsky performance score
(KPS) were measured before and after resection. The extent of resection (EOR) was volumetrically
quantified. Patients were stratified into two subcohorts: treated before (A) and after (B) the foundation
of the Regensburg NOC. The EOR and the PFS and OS were evaluated. Results: Prognostic factors
for PFS and OS were age, preoperative KPS, O6-methylguanine-DNA-methyltransferase (MGMT)
promoter methylation status, isocitrate dehydrogenase 1 (IDH1) mutation status and EOR. Patients
with volumetrically defined complete resection had significantly better PFS (9.4 vs. 7.8 months;
p = 0.042) and OS (18.4 vs. 14.5 months; p = 0.005) than patients with incomplete resection.
The frequency of transient or permanent postoperative neurological deficits was not higher after
complete resection in both subcohorts. The frequency of complete resection was significantly
higher in subcohort B than in subcohort A (68.2% vs. 34.8%; p = 0.007). Accordingly, subcohort
B showed significantly longer PFS (8.6 vs. 7.5 months; p = 0.010) and OS (18.7 vs. 12.4 months;
p = 0.001). Multivariate Cox regression analysis showed complete resection, age, preoperative
KPS, and MGMT promoter status as independent prognostic factors for PFS and OS. Our data
show a higher frequency of complete resection in patients with GBM after the establishment of a
Brain Sci. 2018, 8, 5; doi:10.3390/brainsci8010005 www.mdpi.com/journal/brainsci
Brain Sci. 2018, 8, 5 2 of 10
series of technical developments that resulted in significantly better PFS and OS without increasing
surgery-related morbidity.
Keywords: resection; glioblastoma; fluorescence guidance; functional imaging; outcome
1. Introduction
Glioblastoma (GBM) is not only the most frequent primary brain tumor in adults [1] but it
also has an exceptionally poor prognosis [2]. Despite optimal treatment consisting of microsurgical
resection followed by concomitant radiochemotherapy and adjuvant chemotherapy, virtually all
tumors recur with a median time to progression of 6.9 months, resulting in an average overall survival
rate of about 16 months [3]. Although no class I evidence is available, many studies have reported
a positive correlation between the extent of resection (EOR) and overall survival in patients with
GBM [4]. Some reports using volumetric quantification of EOR have indicated a threshold beyond
which a significant survival benefit has to be achieved [5,6]. Yet, the German Glioma Network Study
has concluded that only complete resection of the contrast-enhancing lesion is superior to biopsy
only [7]. Because of the infiltrative growth pattern, an additional clinical benefit may be obtained
by supramarginal resection [8–10]. However, the best validated treatment standard is still maximal
resection of the contrast-enhancing area. An important limitation to maximal surgical resection is
the potential hazard of inducing surgery-related neurological impairment with detrimental effects
on patient outcome [11,12]. Taken together, the current neurosurgical paradigm in the management
of GBM is maximal resection while avoiding additional neurological morbidity. To achieve this
goal, specialized neuro-oncological centers (NOC) have been established that use a large portfolio
of diagnostic and therapeutic tools. Optimal resection results are achieved by the implementation of
these technical innovations in neurosurgery that should improve patient outcome [13]. The aim of our
study was to investigate whether the foundation of a large volume NOC with an optimized technical
framework leads to better resection results and improved progression-free and overall survival in
patients with newly diagnosed GBM.
2. Materials and Methods
2.1. Patient Population
The study was approved by the Ethics Committee of the University of Regensburg (protocol
15-101-0065) and conducted in accordance with the ethical guidelines of the Helsinki Declaration.
Each patient signed an informed consent form for participation of this trial. Three hundred and
ninety-three patients treated for newly diagnosed GBM at the University Medical Center Regensburg
were screened between 2005 and 2013. From the screened population, 92 (23.5%) patients received a
biopsy only and were excluded. From the remaining 301 patients, preoperative high-quality magnetic
resonance imaging (MRI) data for volumetric EOR analysis were available for 149 patients. This cohort
was selected for volumetric analysis of pre- and post-operative tumor volume and the resulting EOR.
The baseline characteristics of the entire study population are described in Table 1. To address
the impact of the NOC foundation, patients were stratified into two groups: Subcohort A was
treated before the NOC foundation (June 2005 to June 2009); subcohort B was treated after the NOC
foundation (July 2009 to December 2013). During NOC development, neurosurgical strategy was
augmented by a series of technical improvements. This consisted of functional MRI, diffusion tensor
imaging (DTI)-based fiber tracking, fluorescence-guided resection and awake craniotomy. In addition,
postsurgical therapy was optimized by the implementation of a coherent, multidisciplinary treatment
matrix consisting of all medical specialties involved in the management of GBM patients [14].
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Table 1. Baseline characteristics of the entire study cohort. All patients were surgically treated for
newly diagnosed GBM.
Parameter (Number (%))
n 149
Sex (f/m) 67/82 (44.9/55.1)
Age (years, mean) 61.8 (range: 26.7–87.8)
Preoperative KPS (%, median) 80 (range: 20–100)
Preoperative MRC-NPS (points, median) 2 (range: 1–5)
MGMT promoter status
Methylated: 50 (33.6)
Unmethylated: 68 (45.6)
Unknown: 31 (20.8)
IDH1 status
Wild type: 144 (96.6)
Mutated: 5 (3.4)
Postsurgical treatment
Stupp 106 (71.1)
Radiation only 15 (10.1)
Chemotherapy only 16 (10.7)
No treatment 12 (8.1)
GBM: Glioblastoma; KPS: Karnofsky performance score; MRC-NPS: Medical Research Council Neurological
Performance Score; MGMT: O6-methylguanine-DNA-methyltransferase; IDH1: isocitrate dehydrogenase 1.
To validate the technical improvement due to the NOC foundation, the frequency of functional
imaging, awake craniotomy, fluorescence-guided surgery, and preoperative positron emission
tomography (PET) scanning were recorded for both subcohorts. Functional independence and
neurological performance were quantified by means of the Karnofsky Performance Score (KPS) and the
Medical Research Council Neurological Performance Score (MRC-NPS). Surgically induced morbidity
was assessed by worsening of the MRC-NPS score. Follow-up consisting of a review of outpatient
records, death certificates from federal registration offices, and contacting the patient’s family or the
patient´s primary physician was completed by March 2017. No patient was lost to follow-up, and the
median follow-up time was 18.3 months.
2.2. Imaging Protocol and EOR Volumetry
MRI imaging was conducted with a 1.5 or 3 Tesla scanner. Imaging sequences consisted of
3D-MPRage iso-volumetric data with 1.0 mm voxel size with and without a gadolinium contrast agent.
Postoperative MRIs were obtained within 72 h after surgery. The imaging data were imported into
Brainlab iPlan cranial software (version 3.0.2., BrainLAB, Munich, Germany). Subsequently, pre- and
postoperative tumor volume was defined based on the gadolinium-enhanced T1 sequences using
manual segmentation of all slices. The preoperative tumor volume was assessed by quantifying all
tissue with pathological enhancement plus the central necrosis of the tumor. Tumor progression was
defined according to revised assessment in neuro-oncology (RANO) criteria as either 25% or more
increase of an enhancing lesion; significant increase of a non-enhancing T2/fluid-attenuated inversion
recovery (FLAIR) lesion or occurrence of any new lesions. In addition, clinical deterioration not
attributable to other non-tumor causes was valued as progression.
2.3. Statistical Analysis
Differences in rates and proportions were assessed by means of contingency tables followed
by a Pearson’s chi-squared test. Overall survival was analyzed using the Kaplan-Meier method,
and Log-rank analysis was used to calculate differences in progression-free and overall survival.
Independent predictive factors for survival were isolated by multivariate analysis using Cox hazard
regression modelling. Based on the recent literature, we have included the most important prognostic
factors into the multivariate analysis: Age, preoperative KPS, MGMT methylation status as well
as resection status. For multivariate cox regression analysis, we have stratified the parameter KPS
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into two groups, >/< 70% [15]. Significance was defined as p < 0.05 (Stata Version 14.0, Stata Corp.,
College Station, TX, USA).
3. Results
In the entire population, surgical resection had significantly improved both KPS and NPS
(p = 0.008) compared to the presurgical status. The mean pre-operative tumor volume was 31.4 mL
(range: 117.3–1.3 mL), the mean post-operative tumor volume 3.1 mL (range: 5.9–0 mL), resulting in a
mean EOR of 90.2% (range: 100–27.4%). 74 patients (49.7%) underwent complete resection, defined
by an EOR of 100%. The established prognostic parameters were not significantly different between
patients with 100% or <100% resection, except for a trend towards a better preoperative KPS in the
100% EOR group (p = 0.073, Table 2). PFS (median 9.4 vs. 7.8 months; p = 0.042) and OS (median 18.4
vs. 14.5 months; p = 0.005; Figure 1A,B) were significantly better in the 100% EOR group. Univariate
analysis revealed age (p = 0.006), preoperative KPS (p = 0.002), MGMT status (p = 0.027), 100% EOR
(p = 0.005) and the treatment period (before or after NOC foundation; p = 0.009) as prognostic factors
for OS. Multivariate Cox regression analysis established 100% EOR as an independent prognostic
parameter for improved OS next to age, treatment period, preoperative KPS, and MGMT promoter
status (Table 3). We did not observe a significant difference in the KPS and NPS improvement rates
between complete and incomplete resection. Most importantly, in the entire cohort the incidence of
surgically induced neurological morbidity did not differ between the EOR 100% group and the <100%
group (5,4% vs. 4.0%; p = 0.983). Comparing the two subcohorts before (A) and after (B), the foundation
of a specialized NOC, we observed a profound change in the neurosurgical strategy that consisted of a
significant increase in preoperative fMRI scanning (13.1% vs. 41.0%; p = 0.002) and fluoroethyl tyrosine
(FET)-PET imaging (19.6% vs. 39.8%; p = 0.026), and fluorescence-guided resection (8.7% vs. 34.0%;
p = 0.002). In contrast, the frequency of awake craniotomy did not significantly differ between the two
subcohorts (8.7% vs. 6.8%; p = 0.944). Interestingly, the change in the neurosurgical treatment pattern
was correlated with a significantly increased rate of complete resections in subcohort B (34.8–68.2%;
p = 0.007, Figure 2) and the mean volumetric EOR (84.3 vs. 96.1%; p = 0.01). Finally, although the
two subgroups treated before and after NOC foundation were well balanced with regard to the main
prognostic parameters (Table 4), PFS (8.6 vs. 7.5 months; p = 0.010) and OS (18.7 vs. 12.4 months;
p = 0.001) were significantly better in subcohort B treated after the NOC foundation (Figure 3A,B).
Table 2. Baseline characteristics of patients with GBM who underwent complete (EOR: 100%) or
incomplete resection (EOR < 100%).
Parameter Complete Resection(Number (%))
Incomplete Resection
(Number (%)) p
n 74 (49.7) 75 (50.3)
Sex (f/m) 34/40 (46.0/54.0) 33/42 (44.0/56.0) 0.941
Age (years, mean) 61.7 (range: 32.9–80.1) 61.8 (range: 26.7–87.8) 0.939
Preoperative KPS (%, median) 90 (range: 60–100) 80 (range: 20–100) 0.073
Preoperative MRC-NPS (points, median) 2 (range: 1–3) 2 (range: 1–5) 0.219
MGMT:
0.746
Methylated 24 (32.4) 26 (34.7)
Unmethylated 34 (45.9) 34 (45.3)
Unknown 16 (21.6) 15 (20.0)
IDH1 status:
0.988Wildtype 71 (97.3) 73(97.3)
Mutated 3 (2.7) 2 (2.7)
Postsurgical treatment:
0.782
Stupp 55 (74.3) 51 (68.0)
Radiation only 6 (8.1) 9 (12.0)
Chemotherapy only 8 (10.8) 8 (10.7)
No treatment 5 (6.8) 7(9.3)
EOR: Extent of resection.
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Table 3. Multivariate analysis of prognostic factors for overall survival in 149 patients with newly
diagnosed GBM.
Parameter Hazard Ratio 95% CI p
Age 1.032 1.014 1.050 0.001
NOC foundation 0.697 0.482 1.008 0.015
Preoperative KPS (>/<70%) 0.971 0.957 0.988 0.001
MGMT 1.47 1.150 1.891 0.002
Resection status: (complete vs. incomplete) 0.981 0.964 0.998 0.032
NOC: neuro-oncology care center.
Table 4. Baseline characteristics of the two patient subcohorts. Group A: Subcohort of patients with
newly diagnosed GBM treated before the foundation of a specialized neuro-oncology center (NOC).
Group B: Subcohort of patients treated after the NOC foundation.
Parameter Group A (Number (%)) Group B (Number (%)) p
n 49 (32.9) 100 (67.1)
Sex (f/m) 21/28 (42.9/57.1) 46/54 (46.0/54.0) 0.717
Age (years, mean) 62.4 (range: 32.1–81.0) 61.5 (range: 26.7–87.8) 0.647
Preoperative KPS (%, median) 80 (range: 40–100) 80 (range: 20–100) 0.658
Preoperative MRC-NPS (points, median) 2 (range: 1–5) 2 (range: 1–4) 0.68
MGMT:
0.431
Methylated 18 (36.7) 32 (32.0)
Unmethylated 20 (40.9) 48 (48.0)
Unknown 11 (22.4) 20 (20.0)
IDH1 status:
0.889Wildtype 47 (95.9) 97 (97.0)
Mutated 2 (4.1) 3 (3.0)
Postsurgical treatment:
0.195
Stupp 30 (61.2) 76 (76.0)
Radiation only 8 (16.3) 7 (7.0)
Chemotherapy only 4 (8.2) 12 (12.0)
No treatment 5 (10.2) 7 (7.0)
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also leads to significant overall survival benefit. 
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Subcohort (B) treated after the NOC foundation showed a significantly higher proportion of complete 
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4. Discussion
The treatment of GBM remains a formidable challenge. The extensive efforts made in basic and
clinical research have substantially increased the understanding of molecular and pathophysiologic
mechanisms but have not significantly improved the clinical management of GBM [16]. New strategies
including antiangiogenesis [17] and immunotherapy [18] have not met their initial expectations.
Until a therapeutic breakthrough can be achieved, it is of paramount importance to improve
the interdisciplinary pattern of care to provide optimal treatment for patients with GBM [13].
Complete microsurgical resection without causing any additional neurological deficits has become
the current paradigm, leading to maximal reduction of the malignant cell pool and improving the
efficacy of adjuvant treatment efforts [19]. Our data show that the efforts invested in the foundation
of a specialized neuro-oncology care center are not only associated with a profound increase in
complete resection rates but also with a significant improvement in both PFS and OS. This result
is in accordance with several reports on improved overall survival rates in more recently treated
patients [20–23]. However, these studies compared patient cohorts before and after the introduction
of a temozolomide-based regimen that may play an important role in the observed improvement in
outcome. To investigate the impact of the quality of primary resection within an interdisciplinary course
of treatment, we analyzed two subcohorts that were well balanced with regard to the postsurgical
treatment pattern.
Our study has a number of limitations. First, stratification according to the NOC foundation is
somewhat artificial, since the acquisition of technical improvements was a continuous rather than
a stepwise process. Still, we were able to show that the preoperative workup intending to define
both the metabolically active tumor area by FET-PET scanning and the optimal resection trajectory
by functional imaging had changed significantly after the NOC foundation. In addition, the number
of fluorescence-guided resections was significantly increased, improving the quality of resection in
GBM [24,25].
Another limitation may be that the relatively small number of patients did not allow for the
definition of an EOR threshold for outcome improvement [26]. However, this aspect was not the
primary focus of this study. Finally, this study has a retrospective, observational design that may
limit the statistical methodology to some degree. In particular, other parameters such as modernized
post-surgical treatment regimen may also have an impact on the better outcome after NOC foundation
in addition to the improved resection results. However, data were extracted from primary databases of
the Tumor Center Regensburg and the University Medical Center Regensburg, so that no patient was
lost to follow-up. We are in the process of validating our results by conducting a prospective registry
trial as a continuous benchmark process with the intent to improve the interdisciplinary treatment
platform for patients with GBM.
5. Conclusions
In conclusion, our data show a profound improvement in neurosurgical treatment after the
foundation of a specialized neuro-oncology center that resulted in a significant survival benefit in
patients with newly diagnosed GBM.
Acknowledgments: No funding was received for this study.
Author Contributions: A.H., C.D., K.-M.S., D.E., and M.G. carried out the data sampling and the statistical
analysis. A.H. wrote the manuscript with support from M.A.P., P.H., K.P., M.J.R., and C.W. and T.P., M.A.P. and
P.H. conceived the original idea. A.B. supervised the project.
Conflicts of Interest: The authors report no conflict of interest concerning the materials or methods used in this
study or the findings specified in this paper.
Brain Sci. 2018, 8, 5 9 of 10
References
1. Ohgaki, H.; Kleihues, P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005, 109, 93–108.
[CrossRef] [PubMed]
2. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507. [CrossRef] [PubMed]
3. Omuro, A.; DeAngelis, L.M. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013, 310,
1842–1850. [CrossRef] [PubMed]
4. Brown, T.J.; Brennan, M.C.; Li, M.; Church, E.W.; Brandmeir, N.J.; Rakszawski, K.L.; Patel, A.S.; Rizk, E.B.;
Suki, D.; Sawaya, R.; et al. Association of the extent of resection with survival in glioblastoma: A systematic
review and meta-analysis. JAMA Oncol. 2016, 2, 1460–1469. [CrossRef] [PubMed]
5. Chaichana, K.L.; Jusue-Torres, I.; Navarro-Ramirez, R.; Raza, S.M.; Pascual-Gallego, M.; Ibrahim, A.;
Hernandez-Hermann, M.; Gomez, L.; Ye, X.; Weingart, J.D.; et al. Establishing percent resection and
residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial
glioblastoma. Neuro Oncol. 2014, 16, 113–122. [CrossRef] [PubMed]
6. Sanai, N.; Polley, M.Y.; McDermott, M.W.; Parsa, A.T.; Berger, M.S. An extent of resection threshold for newly
diagnosed glioblastomas. J. Neurosurg. 2011, 115, 3–8. [CrossRef] [PubMed]
7. Kreth, F.W.; Thon, N.; Simon, M.; Westphal, M.; Schackert, G.; Nikkhah, G.; Hentschel, B.; Reifenberger, G.;
Pietsch, T.; Weller, M.; et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the
era of radiochemotherapy. Ann. Oncol. 2013, 24, 3117–3123. [CrossRef] [PubMed]
8. Yan, J.L.; van der Hoorn, A.; Larkin, T.J.; Boonzaier, N.R.; Matys, T.; Price, S.J. Extent of resection of
peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma
patients. J. Neurosurg. 2017, 126, 234–241. [CrossRef] [PubMed]
9. Eyupoglu, I.Y.; Hore, N.; Merkel, A.; Buslei, R.; Buchfelder, M.; Savaskan, N. Supra-complete surgery via
dual intraoperative visualization approach (diva) prolongs patient survival in glioblastoma. Oncotarget 2016,
7, 25755–25768. [CrossRef] [PubMed]
10. Li, Y.M.; Suki, D.; Hess, K.; Sawaya, R. The influence of maximum safe resection of glioblastoma on survival
in 1229 patients: Can we do better than gross-total resection? J. Neurosurg. 2015. [CrossRef] [PubMed]
11. Gulati, S.; Jakola, A.S.; Nerland, U.S.; Weber, C.; Solheim, O. The risk of getting worse: Surgically acquired
deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma.
World Neurosurg. 2011, 76, 572–579. [CrossRef] [PubMed]
12. Jakola, A.S.; Gulati, S.; Weber, C.; Unsgard, G.; Solheim, O. Postoperative deterioration in health related
quality of life as predictor for survival in patients with glioblastoma: A prospective study. PLoS ONE 2011, 6,
e28592. [CrossRef] [PubMed]
13. Khan, U.A.; Bhavsar, A.; Asif, H.; Karabatsou, K.; Leggate, J.R.; Sofat, A.; Kamaly-Asl, I.D. Treatment by
specialist surgical neurooncologists improves survival times for patients with malignant glioma. J. Neurosurg.
2015, 122, 297–302. [CrossRef] [PubMed]
14. Bunnell, C.A.; Weingart, S.N.; Swanson, S.; Mamon, H.J.; Shulman, L.N. Models of Multidisciplinary Cancer
Care: Physician and Patient Perceptions in a Comprehensive Cancer Center. J. Oncol. Pract. Am. Soc.
Clin. Oncol. 2010, 6, 283–288. [CrossRef] [PubMed]
15. Lamborn, K.R.; Chang, S.M.; Prados, M.D. Prognostic Factors for Survival of Patients with Glioblastoma:
Recursive Partitioning Analysis. Neuro Oncol. 2004, 6, 227–235. [CrossRef] [PubMed]
16. Bianco, J.; Bastiancich, C.; Jankovski, A.; des Rieux, A.; Preat, V.; Danhier, F. On glioblastoma and the search
for a cure: Where do we stand? Cell. Mol. Life Sci. 2017, 74, 2451–2466. [CrossRef] [PubMed]
17. Diaz, R.J.; Ali, S.; Qadir, M.G.; De La Fuente, M.I.; Ivan, M.E.; Komotar, R.J. The role of bevacizumab in the
treatment of glioblastoma. J. Neurooncol. 2017, 133, 455–467. [CrossRef] [PubMed]
18. Huang, J.; Liu, F.; Liu, Z.; Tang, H.; Wu, H.; Gong, Q.; Chen, J. Immune checkpoint in glioblastoma: Promising
and challenging. Front. Pharmacol. 2017, 8, 242. [CrossRef] [PubMed]
19. Eyupoglu, I.Y.; Buchfelder, M.; Savaskan, N.E. Surgical resection of malignant gliomas-role in optimizing
patient outcome. Nat. Rev. Neurol. 2013, 9, 141–151. [CrossRef] [PubMed]
20. Gramatzki, D.; Dehler, S.; Rushing, E.J.; Zaugg, K.; Hofer, S.; Yonekawa, Y.; Bertalanffy, H.; Valavanis, A.;
Korol, D.; Rohrmann, S.; et al. Glioblastoma in the canton of zurich, switzerland revisited: 2005 to 2009.
Cancer 2016, 122, 2206–2215. [CrossRef] [PubMed]
Brain Sci. 2018, 8, 5 10 of 10
21. Woehrer, A.; Bauchet, L.; Barnholtz-Sloan, J.S. Glioblastoma survival: Has it improved? Evidence from
population-based studies. Curr. Opin. Neurol. 2014, 27, 666–674. [CrossRef] [PubMed]
22. Nava, F.; Tramacere, I.; Fittipaldo, A.; Bruzzone, M.G.; Dimeco, F.; Fariselli, L.; Finocchiaro, G.; Pollo, B.;
Salmaggi, A.; Silvani, A.; et al. Survival effect of first- and second-line treatments for patients with primary
glioblastoma: A cohort study from a prospective registry, 1997–2010. Neuro Oncol. 2014, 16, 719–727.
[CrossRef] [PubMed]
23. Koshy, M.; Villano, J.L.; Dolecek, T.A.; Howard, A.; Mahmood, U.; Chmura, S.J.; Weichselbaum, R.R.;
McCarthy, B.J. Improved survival time trends for glioblastoma using the seer 17 population-based registries.
J. Neurooncol. 2012, 107, 207–212. [CrossRef] [PubMed]
24. Leroy, H.A.; Vermandel, M.; Lejeune, J.P.; Mordon, S.; Reyns, N. Fluorescence guided resection and
glioblastoma in 2015: A review. Lasers Surg. Med. 2015, 47, 441–451. [CrossRef] [PubMed]
25. Schucht, P.; Seidel, K.; Beck, J.; Murek, M.; Jilch, A.; Wiest, R.; Fung, C.; Raabe, A. Intraoperative Monopolar
Mapping During 5-Ala-Guided Resections of Glioblastomas Adjacent to Motor Eloquent Areas: Evaluation
of Resection Rates and Neurological Outcome. Neurosurg. Focus 2014, 37, E16. [CrossRef] [PubMed]
26. Solheim, O.; Gulati, S.; Jakola, A.S. Glioblastoma resection: In search of a threshold between worthwhile and
futile. Neuro Oncol. 2014, 16, 610–611. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
